1. Stocks
    2. /
  2. BioNTech Se (NASDAQ: BNTX)
    3. /

BioNTech Se (NASDAQ: BNTX) Share Price and News

$111.61 $-5.78 (-4.9%) Thursday, 19 December 2024 at 8:00:00 am Australian Eastern Daylight Time

BioNTech Se Chart and Price Data

About BioNTech Se

Last updated 19-12-2024, 08:00:00am AEDT
Current Price $111.61
Change $-5.78 (-4.9%)
Close Price $111.61
Open Price $116.00
Bid $109.00
Ask $118.00
Day Range $110.02 - $117.11
Year Range $76.53 - $131.49
Volume 800,764
Average Volume 904,840
Market Cap $28,143,078,600.00
Earnings Per Share $-2.15

    • BioNTech Se (NASDAQ: BNTX)
    Latest News

    Ask a Fund Manager

    4 healthcare share tips from a fundie with a health PhD

    | Tony Yoo

    Ask A Fund Manager: Platinum Asset Management's Dr Bianca Ogden picks 2 medical stocks still under the radar, plus 2…

    Read more »

    asx share associated with COVID vaccine represented by lab tech drawing down syringe
    International Stock News

    Pfizer to develop mRNA vaccines without BioNTech

    | Cory Renauer

    The pharmaceutical heavyweight thinks it won't need any more help to whip up new mRNA-based vaccines.

    Read more »

    coronavirus vaccine represented by gloved hand drawing down from syringe
    International Stock News

    Johnson & Johnson coronavirus vaccine wins FDA authorisation

    | Eric Volkman

    The big pharmaceutical company's jab has some important advantages.

    Read more »

    Vaccine vials sitting on top of a pile of US cash
    International Stock News

    The most popular coronavirus stock may lose half its value by 2023

    | Sean Williams

    This as-of-now unstoppable COVID-19 stock might be one of the worst investments going forward.

    Read more »

    vials of medication labelled with COVID-19 vaccine stickers
    Share Market News

    CSL (ASX:CSL) share price on watch after hints of 'far more robust' vaccine

    | Bernd Struben

    Australian global biotech giant CSL Limited didn't win the sprint for a coronavirus vaccine. But it may lead the marathon.

    Read more »

    woman waering face mask holding vial of covid-19 vaccine
    International Stock News

    Why Pfizer and BioNTech stocks popped Wednesday

    | Joe Tenebruso

    The healthcare leaders became the first to receive emergency authorization for their coronavirus vaccine.

    Read more »

    doctor holding covid-19 vaccine bottle
    International Stock News

    3 key advantages Moderna holds over Pfizer and AstraZeneca

    | Keith Speights

    They could add up to make Moderna a much bigger winner for investors than either of the two big pharma…

    Read more »

    Doctor holding small world globe in one hand and a Covid vaccine needle in the other
    International Stock News

    Why AstraZeneca's potential vaccine is more exciting than you think

    | Jason Hawthorne

    Investors are missing the big picture in the drugmaker's vaccine announcement.

    Read more »

    Cash piled up in the middle of a bear trap symbolising risky investments
    International Stock News

    Why Moderna Is Less Risky Than You Think

    | Manali Bhade

    Its coronavirus vaccine will likely be successful; its technology has huge potential; and the company has a healthy balance sheet.

    Read more »

    small figure representing ASX shares with cape and shield fighting coronavirus
    Share Gainers

    With the Moderna (NASDAQ:MRNA) share price blasting up, have the forward-looking markets got it right?

    | Bernd Struben

    The Moderna (NASDAQ: MRNA) share price is going gangbusters as the world awaits results of its COVID-19 vaccine trial. Let's…

    Read more »

    vials of medication labelled with COVID-19 vaccine stickers
    International Stock News

    Here's why Moderna's coronavirus vaccine could outsell Pfizer's

    | Alex Carchidi

    Moderna's candidate is cool with being kept at warmer temperatures.

    Read more »

    A health worker drug testing in a lab to find 'covid-19 vaccine' representing covid shares
    International Stock News

    New data shows higher efficacy rate for Pfizer and BioNTech coronavirus vaccine candidate

    | Eric Volkman

    The 2 companies plan to submit BNT162b2 for emergency use authorisation in the very near future.

    Read more »

    Profile

    since

    Note